

## Honey and Cardiovascular Risk Factors, in Normal Individuals and in Patients with Diabetes Mellitus or Dyslipidemia

Noori Al-Waili,<sup>1</sup> Khelod Salom,<sup>1</sup> Ahmad Al-Ghamdi,<sup>2</sup> Mohammad Javed Ansari,<sup>2</sup>  
Ali Al-Waili,<sup>1</sup> and Thia Al-Waili<sup>1</sup>

<sup>1</sup>Waili Foundation for Science, Queens, New York, USA.

<sup>2</sup>Unit of Bee Research, Department of Plant Protection,  
College of Food and Agricultural Sciences, King Saud University, Riyadh, Saudi Arabia.

**ABSTRACT** Diabetes mellitus, hypercholesteremia, hypertension (HTN), and obesity are well-known risk factors for cardiovascular diseases (CVD). Various medications are currently in use for management of these comorbidities. Undesirable side effects are unavoidable and the ultimate and ideal goal is hardly achieved. Honey and other bee products are widely used in traditional medicine for management of many diseases. Others and the authors have found potent biological activities of these products. Honey is now reintroduced in modern medicine as part of wound and burn management. Honey has antioxidant, anti-inflammatory, and antimicrobial activities. More studies are exploring other aspects of honey activity such as its effect on blood sugar, body weight, lipid profile, C-reactive protein, nitric oxide, proinflammatory prostaglandins, and homocysteine. Growing evidence and scientific data support the use of honey in patients with diabetes, HTN, dyslipidemia, obesity, and CVD. This review discusses clinical and preclinical studies on potential influence of honey on diabetes mellitus and cardiovascular risk factors, and emphasizes the importance of conducting more clinical and controlled studies.

**KEY WORDS:** • cholesterol • C-reactive protein • glucose • honey • insulin • obesity • triacylglycerol

### INTRODUCTION

CARDIOVASCULAR DISEASES (CVD) are associated with hypercholesterolemia, hypertension (HTN) and diabetes mellitus (DM). Atherosclerosis, which is due to endothelial dysfunction, is the main cause of CVD. Cardiovascular disorders remain the leading cause of death worldwide.<sup>1</sup> Obese and diabetic patients have a high risk of dying from complications associated with CVD.

In addition to normal BMI and blood pressure, maintaining normal levels of serum homocysteine, C-reactive protein (CRP), lipids, and insulin are essential to maintain a healthy cardiovascular system. Normal biological activities of the vasoactive factors, nitric oxide (NO) and prostaglandins are important to maintain a healthy heart and blood vessels.

Humans have used bee products in folk medicine since ancient times. Ancient religious texts mentioned honey as a popular remedy. In this regard, the Talmud, the Old and New Testaments of the Bible, and the Holy Quran (1400 years ago) mentioned honey as a cure for diseases. A large

chapter (SORA) appears in the Holy Quran named BEE (Al Nahl) and part of it says: “And thy LORD taught the bee to build its cells in hills, on trees and in men’s habitations, then to eat of all the produce of the earth and find with skill the spacious paths of its LORD, there issues from within their bodies a drink of varying colors, wherein is healing for men, verily in this is a sign for those who give thought.”

The health benefits attributed to bee products are based on anecdotes or public observations with limited scientific data. However, during the last few decades, these products have been subjected for analysis and testing. Others and the authors have published numerous scientific data showing the medicinal and nutritional values of bee products.<sup>2–6</sup> The literature shows that honey has antibacterial, antifungal, antiviral, anti-inflammatory, antihypertensive, antioxidant, antitumor, cardioprotective, hepatoprotective, and hypoglycemic properties.<sup>3,4,6–15</sup> A recent review showed that the polyphenol content of various types of honey might prevent CVD by improving coronary vasodilatation, decreasing the ability of platelets in the blood to clot, and preventing low-density lipoproteins (LDL) from oxidizing.<sup>16</sup> Therefore, honey has received renewed interest as an important natural substance that can be used in new therapies almost free from side effects that are encountered with the use of synthetic and chemical medicines.

Manuscript received November 14, 2012. Revision accepted August 22, 2013.

Address correspondence to: Noori Al-Waili, MD, PhD, DGO, CHT, Waili Foundation for Science, Queens, NY 11418, USA, E-mail: drnoori6@yahoo.com

TABLE 1. THE MAIN SOLID CONTENTS OF HONEY

Groups	Members	References
Carbohydrates	Dextrose and fructose account for about 85% of the solids in honey. Ten disaccharides present in honey: sucrose, maltose, isomaltose, maltulose, nigerose, turanose, kojibiose, laminaribiose, a, B-trehalose, and gentiobiose. Ten trisaccharides are present: melezitose, 3-a-isomaltosylglucose, maltotriose, 1-kestose, panose, isomaltotriose, erlose, theanderose, centose, and isopanose. Two more complex sugars, isomaltotetraose and isomaltopentaose, have been determined	25,28,39
Nonaromatic organic acids	Butyric, malic, maleic, citric, succinic, fumaric, oxalic, pyroglutamic acids, and gluconic acid	24,31,32,41
Trace elements and minerals	Aluminum, lead, arsenic, lithium, barium, molybdenum, boron, nickel, bromine, rubidium, cadmium, silicon, chlorine, strontium, sulfur, florid, vanadium, iodide, zirconium, cobalt, sodium, calcium, potassium, magnesium, phosphorus, zinc, copper, iron, manganese, chromium, and selenium	25,27,32,40,42
Vitamins	Thiamin, riboflavin, pyridoxin, vitamin A, niacin, panthothenic acid, phyllochinon, vitamin E, and ascorbic acid	24,25,27
Amino acids	Eighteen essential and nonessential amino acids; proline, glutamic acid, alanine, phenylalanine, tyrosine, leucine, and isoleucine are the most common	24,27,28
Enzymes	Glucose oxidase, invertase, amylase, catalase, and acid phosphatase	30,33
Polyphenols	Phenolic acids, flavonoids, and phenolic acid derivatives; quercetin, chrysin, galangin, luteolin, kaempferol, and apigenin are the main flavonoids in honey	20–23,34–36
NO	NO end products	37,38,42

NO, nitric oxide.

## DISCUSSION

### Honey composition

Honey is a carbohydrate-rich syrup produced by bees, from floral nectars. Color, flavor, and aroma depend on its floral origin. Aberrantly, honey composition is tightly associated to its botanical origin, which is closely related to the geographical area in which it is originated. In this regard, soil and climate characteristics determine melliferous flora, in addition to the presence of different minerals in soil.<sup>17</sup> The organoleptic characteristics of honey are strongly dependent on its botanical origin and to some extent on its geographical origin.<sup>18</sup>

Composition of different honeys from many regions of the world has been studied, including the United Arab Emirates (U.A.E.), the United States, Algeria, India, Slovenia, Bangladesh, and Malaysia.<sup>19–25</sup> Honey contains 181 bioactive substances.<sup>26</sup> More than 500 different volatile compounds were identified in various types of honey.<sup>27</sup> Fructose and glucose are the major components while disaccharides, trisaccharides, and oligosaccharides are present in small quantities. In addition, honey contains protein, enzymes, amins acids, vitamins, and minerals (Table 1).<sup>20–25,27–42</sup>

The physical chemistry characteristics of honey are directly related to floral origin.<sup>30,31</sup> Approximately 30 nonaromatic organic acids have been identified.<sup>32</sup> Gluconic acid is the major organic acid produced by enzymatic glucose oxidase reaction. The glucose oxidase reaction in honey produces glutamic acid and hydrogen peroxide from glucose. Invertase converts sucrose to fructose and glucose.<sup>33</sup> Amylase splits starch chains

yielding dextrans and maltose.<sup>30</sup> Polyphenols are an important group of compounds present in honey.<sup>34–36</sup>

An analytical survey of U.S. honey was reported.<sup>28</sup> This includes analyses of 490 samples of U.S. floral honey and 14 samples of honeydew honey gathered from 47 of the 50 states and representing 82 single floral types and 93 blends of known composition. Floral honey is higher in fructose and dextrose, lower in disaccharides and higher sugars, and contains much less acid. The water content of honey varies greatly, ranging between 13% and 25%. We have analyzed honey collected from the U.A.E.; the acidity was 13%, and the composition includes (out of 100 g): fructose 38 g, glucose 30 g, moisture 29 g, vitamin C 2.3 mg, copper 0.098 mg, zinc 0.6 mg, vitamin E 0.74 mg, vitamin A 0.49 mg, selenium 0.44 mg, chromium 0.007 mg, iron 0.2 mg, cobalt 0.016 mg, calcium 17 mg, glutathione reductase 0.52 mg, and the remainder consist of other carbohydrates, proteins, and unidentified substances.<sup>25</sup>

Electric conductivity, acidity, amino acids, mineral content, carbohydrate content, and pollen proteins are used to assess provenience of honey.<sup>39,40,43–45</sup> Seventeen minerals in Spanish honey have been determined, reporting a relationship between mineral contents and geographical origin.<sup>40</sup> The authenticity of Galician-labeled honey has been confirmed by analyzing elemental composition of honey combined with chemometrics modeling techniques.<sup>45</sup> Further, it was found that  $\text{NO}_3^-$  is a potential reliable marker of a honey's origin and quality.<sup>42</sup> The acids have been used as factors for the characterization of both botanical and geographical origins of honeys.<sup>41</sup>

TABLE 2. EFFECTS OF HONEY ON BLOOD SUGAR IN NORMAL INDIVIDUALS

<i>Study</i>	<i>Origin of honey</i>	<i>Number of individuals</i>	<i>Results</i>
Robert <i>et al.</i> (2009) <sup>46</sup>	Malaysia and Australia	8	Mean AUC/glycemic index of both honeys were significantly less than that after glucose
Deibert <i>et al.</i> (2010) <sup>47</sup>	Germany; eight samples of honey	10	5/8 samples of honey show a low glycemic index
Münstedt <i>et al.</i> (2008) <sup>48</sup>	Germany; basswood honey	12	Serum insulin, C-peptide, and glucose values at 60 min were significantly lower for honey. AUC for glucose response was lower for the honey than the honey-comparable glucose-fructose solution
Ischayek and Kern. (2006) <sup>49</sup>	United States; clover, buckwheat, cotton, and tupelo honey	12	No significant differences in glycemic index between the honey samples
Shambaugh <i>et al.</i> (1990) <sup>50</sup>	United States	33	Sucrose gave higher PGL readings than honey, producing significantly greater glucose intolerance
Ahmad <i>et al.</i> (2008) <sup>51</sup>	Pakistan	26	Glycemic responses were significantly lower in subjects who consumed natural honey than those who consumed glucose or artificial honey
Yaghoobi <i>et al.</i> (2008) <sup>52</sup>	Iran	38	Honey reduces fasting PGL (4.2%) compared with sucrose
Al-Waili (2008) <sup>25</sup>	United Arab Emirates	10	Honey reduced fasting blood sugar by 5%
Al-Waili (2003) <sup>14</sup>	United Arab Emirates	24	Honey inhalation lowers PGL and elevates plasma insulin and C-peptide
Al-Waili (2004) <sup>53</sup>	United Arab Emirates	16	In glucose tolerance test, dextrose raised PGL at 1 h (53%) and 2 h (3%), and lowered PGL after 3 h by 20%. Honey elevated PGL after 1 h by 14% and decreased it after 3 h by 10%. Elevation of insulin and C-peptide was significantly higher after dextrose than after honey. Daily consumption of 75 g of honey for 15 days reduced fasting PGL by 6%

AUC, area under curve; PGL, plasma glucose level.

### *Honey and glycemic response*

Many studies showed that honey from various origins has almost similar activity on blood sugar (Table 2).<sup>14,25,46–53</sup> Glycemic index of Malaysian honey and Australian honey was studied in eight healthy volunteers. The patients received 50 g carbohydrate; two varieties of honey or the reference food. The results showed that the mean area under curve and glycemic index of the Malaysian and Australian honeys did not differ from each other but were significantly less than that after glucose.<sup>46</sup> In Germany, eight various German honeys differing in their floral source and carbohydrate composition were tested. Ten healthy fasting individuals received isoglucidic test meals (25 g carbohydrate) and a 25 g glucose reference. Five of the eight tested samples of honey showed a low glycemic index below 55. In addition, the glycemic index and insulinemic index significantly correlated with the fructose content of honey varieties.<sup>47</sup> Another study compared the effects of basswood honey, an identical sugar solution (containing 75 g of glucose), and oral glucose tolerance test solution on serum glucose, insulin, and C-peptide values in 12 healthy subjects.<sup>48</sup> Serum insulin, C-peptide, and glucose values at 60 min were significantly lower for honey. The area under

the concentration-time profile for glucose response was lower for honey than the honey-comparable glucose-fructose solution. Honey had less effect on serum glucose, C-peptide, and insulin values than the honey-comparable glucose-fructose solution.<sup>48</sup>

In the United States, the glycemic index of a 250 mL solution serving of clover, buckwheat, cotton, and tupelo honey providing 50 g carbohydrate were assessed in 12 healthy adults, relative to triplicate feedings of 50 g carbohydrate as a glucose solution.<sup>49</sup> No significant differences in glycemic index between these varieties of honey were found, and there was no relationship between glycemic index and the fructose-to-glucose ratio. Therefore, small differences in fructose-to-glucose ratios do not substantially affect honey glycemic index.<sup>49</sup>

In another U.S. study, oral glucose tolerance testing comparing sucrose, fructose, and honey was conducted in 33 individuals. Fructose showed minimal changes in plasma glucose level (PGL) while sucrose gave higher PGL readings than honey, producing significantly greater glucose intolerance.<sup>50</sup>

In Pakistan, oral glucose tolerance test was conducted in 26 healthy individuals with use of natural honey, simulated honey, or D-glucose (1 g/kg body weight). Glucose response

was significantly lower in the natural honey group compared with the artificial honey and D-glucose groups.<sup>51</sup> At 60 min, individuals in D-glucose and simulated honey group exhibited 20% increments in PGL compared with natural honey group. However, at 180 min, 20% decrease in PGL was observed in the D-glucose group compared with 9.75% reduction in the honey group. Therefore, glycemic responses were significantly lower in subjects who consumed natural honey than those who consumed glucose or artificial honey.<sup>51</sup>

Another study from Iran has shown that a regimen of a 30-day natural honey intake (70 g) in 38 overweight individuals slightly reduced fasting PGL (4.2%) compared with 70 g of sucrose.<sup>52</sup>

In the U.A.E., 10 normal individuals received a normal diet supplemented with daily consumption of 1.2 g/kg body weight honey dissolved in 250 mL of water during a 2-week test period. Honey reduced fasting blood sugar by 5% after 2 weeks.<sup>25</sup> In 24 normal individuals, 10% dextrose inhalation caused mild reduction of plasma insulin and C-peptide and unremarkable changes in PGL. Honey inhalation caused lowering of PGL and elevation of plasma insulin and C-peptide.<sup>14</sup> In eight healthy subjects, effects of dextrose solution (250 mL of water containing 75 g of dextrose) or honey solution (250 mL of water containing 75 g of natural honey) on PGL was studied in the U.A.E. Further, in eight other normal individuals, effects of honey solution, administered for 15 days, on PGL was studied. It was found that dextrose raised PGL at 1 h (53%) and 2 h (3%), and lowered PGL after 3 h by 20%. Honey elevated PGL after 1 h by 14% and decreased it after 3 h by 10%. Elevation of insulin and C-peptide was significantly higher after dextrose than after honey. In addition, daily consumption of 75 g of honey for 15 days reduced fasting PGL by 6%.<sup>53</sup>

In the U.A.E., food restriction with 50% honey feeding in rats caused greater reduction in fasting blood sugar compared with total food restriction with 50% dextrose feeding. Similar results were obtained after acute blood loss in rats on total food restriction with 50% honey feeding compared with the other groups.<sup>54</sup> In addition, the authors assessed the effects of four diets on blood variables in rats: a commercial regular diet as control, total food restriction with honey, a commercial regular diet with dextrose, or total food restriction with dextrose after administering carbon tetrachloride. Honey feeding ameliorated reduction in PGL observed after carbon tetrachloride toxicity.<sup>55</sup>

Intravenous infusion of 40 g of honey collected in the U.A.E. in healthy sheep caused elevation of PGL for 90 min postinfusion, whereas it decreased PGL at 2 and 3 h postinfusion compared with fasting blood sugar. Dextrose caused significant elevation of PGL at all time intervals. Similar results were obtained with the use of 10% dextrose compared to 80 g of honey. Inhalation of honey caused significant lowering of PGL during and after inhalation compared with water inhalation.<sup>56</sup>

In the United Kingdom, hyperglycemic effects of glucose, sucrose, and honey equivalent to 20 g in 12 normal volunteers were studied. Honey attenuated the postprandial glycemic response in normal volunteers.<sup>57</sup>

### Honey and diabetes

**Animal experimentation.** In Malaysia, honey (0.2, 1.2, and 2.4 g/kg/day) given by oral gavage for 4 weeks significantly increased body weight, total antioxidant status, activities of catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, and superoxide dismutase activity in diabetic rats. In addition, honey ameliorated side effects of DM on kidney rats and significantly reduced fasting blood sugar.<sup>8</sup> Tualang honey significantly reduced elevated malondialdehyde levels in streptozotocin-induced diabetic rats and restored superoxide dismutase and catalase activities. These results suggest that hypoglycemic effect of tualang honey might be attributed to its antioxidative effect on the pancreas.<sup>13</sup> In streptozotocin-induced diabetic rats, it was found that the combination of glibenclamide or metformin with honey improved glycemic control. Glibenclamide or metformin combined with honey significantly reduced the elevated levels of creatinine, bilirubin, triacylglycerol, and VLDL.<sup>58</sup>

In Pakistan, oral administration of *Apis florea* (small-bee) and *Apis dorsata* (large-bee) honey in a dose of 5 mL/kg did not produce a significant increase in PGL in normal and alloxan-diabetic rabbits, whereas the adulterated honey significantly raised the PGL in normal and hyperglycemic rabbits.<sup>59</sup> In higher doses of 10 mL/kg and 15 mL/kg body weight, all the three honeys produced a significant rise in PGL of normal and alloxan-diabetic rabbits.<sup>59</sup> In this study, the animals received very high doses of the interventions and that may be why PGL increased in all groups.

In New Zealand, a study conducted on rats showed that HbA1c levels were significantly reduced in 10% honey-fed compared with rats fed 7.9% sucrose or a sugar-free diet.<sup>60</sup>

**Human experimentation.** In the United Kingdom, hyperglycemic effects of glucose, sucrose, and honey equivalent to 20 g in eight patients with type 1 DM, and six patients with type 2 DM were studied. Honey attenuated postprandial glycemic response in the patients with DM.<sup>57</sup> In Italy, honey, compared to an isoglucidic amount of bread, had no additional hyperglycemic effect in 21 type 2 diabetic individuals when consumed for breakfast.<sup>61</sup> In Greece, the metabolic effects of honey (alone or combined with other foods) were investigated in 31 type 2 diabetics. Honey caused a hyperglycemia similar to that produced by consuming bread in individuals with type 2 diabetes.<sup>62</sup>

In India, 30 individuals with a proven parental history of type 2 DM were subjected to an oral glucose tolerance test with the use of either honey or glucose. The subjects with impaired glucose tolerance showed significantly lower PGL after consumption of honey in comparison with the glucose tolerance test. In diabetic patients, high degree of tolerance to honey was recorded too.<sup>63</sup>

In Egypt, a case-control cross-sectional study was conducted on 20 children and adolescents with type 1 DM and 10 healthy children and adolescents. Oral glucose tolerance tests using glucose, sucrose, or honey were conducted measuring fasting and postprandial serum C-peptide levels. Honey, compared with sucrose, had a lower glycemic index and incremental index in both diabetic patients and control.<sup>64</sup>



In the U.A.E., the effects of 70 g of dextrose or 90 g of honey on PGL in seven patients with type 2 DM and the effects of 30 g of sucrose or 30 g of honey on PGL, plasma insulin, and plasma C-peptide in five diabetic patients were studied.<sup>53</sup> Honey compared with dextrose caused a significantly lower rise of PGL. Elevation of PGL was greater after honey than after sucrose at 30 min, and was lower after honey than it was after sucrose at 60, 120, and 180 min. Honey caused a greater elevation of insulin than sucrose did after 30, 120, and 180 min in diabetics.

Sixteen patients with type 2 DM were treated with intrapulmonary inhalation of honey. Fasting PGL was estimated in each patient and was re-estimated during 3 h after honey inhalation, at 30 min intervals. Glucose tolerance tests were performed in another eight patients with type 2 DM and after 1 week, the procedure was repeated with inhalation of honey after ingestion of glucose. Honey inhalation caused lowering of PGL and elevation of plasma insulin and C-peptide, and significantly reduced random PGL after 30 min. Fasting PGL was reduced after honey inhalation at hour three postinhalation, which was significant at hour three. Honey inhalation was effective in reducing PGL, suggesting it could improve glucose tolerance and elevate plasma insulin and C-peptide in diabetic patients.<sup>14</sup>

The blood glucose and plasma insulin responses to some simple carbohydrates (glucose, fructose, and lactose) and honey were studied in 32 type 2 DM patients. Ingestion of 25 g glucose, fructose, or lactose, or 30 g honey was tested. Sixty minutes after ingestion of each meal, the increases in PGL and in plasma insulin were significantly higher after glucose, fructose, and lactose than after honey.<sup>65</sup>

The above studies showed that honey collected from different regions had almost similar glycemic effect. Honey compared with dextrose reduced PGL and insulin in normal subjects. This is important since hyperinsulinemia is a single independent determinant for coronary artery diseases and it increases homocysteine in healthy normal weight, overweight, and obese premenopausal women.<sup>66</sup> Hyperglycemia increases circulatory cytokine concentrations by an oxidative mechanism, particularly in subjects with impaired glucose tolerance.<sup>67</sup> Table 3 summarizes studies conducted on patients with type 1 and type 2 diabetes.<sup>14,53,57,61-64</sup>

*Mechanism of action.* Honey contains fructose, oligosaccharides, minerals, and antioxidants.<sup>19-25</sup> In normal individuals, a daily consumption of 1.2 g/kg body weight honey during a 2-week test increased blood vitamin C concentration by 47%,  $\beta$ -carotene by 3%, uric acid by 12%, and glutathione reductase by 7%. Honey increased serum copper by 33%.<sup>25</sup>

Many studies have shown that flavonoids exert diverse normoglycemic effects and lead to a lower incidence of complications associated with DM.<sup>68-70</sup> Antioxidants such as myricetin, fisetin, quercetin, and their glycoside precursor (isoquercitrin) showed a strong inhibition of the fructose and glucose transport mediated by GLUT2.<sup>71</sup> These compounds are all present in beehive products.<sup>72</sup>

Zinc lowers PGL by improvement of insulin sensitivity and copper sulfate significantly decreases PGL.<sup>73,74</sup> Zinc and copper are important for insulin and glucose metabolism; both minerals were increased with consumption of honey.<sup>25</sup>

We have found that honey reduces prostaglandin levels and elevates NO.<sup>37,38,75</sup> It has been shown that prostaglandin E2 is one of the main physiological inhibitors of insulin.<sup>76</sup> Higher levels of NO and various NO donors stimulate insulin secretion.<sup>77</sup> Glycemic carbohydrates present in natural honey decrease saccharide absorption.<sup>78-79</sup> It has been found that hydrogen peroxide can effectively mimic the function of insulin.<sup>80</sup> Oligosaccharides may play a role in the anti-diabetic effect of honey.<sup>81-83</sup> Oligosaccharides delayed gastric emptying, slowed rate of digestion, and delayed intestinal absorption.<sup>84-87</sup>

Infusion of small amounts of fructose induced amplification of the counter regulatory response to mild hypoglycemia in normal individuals.<sup>88</sup> It has been proposed that due to presence of fructose in addition to glucose, the augmentation of hormonal response to hypoglycemia by using honey might have a place in the prevention of hypoglycemia frequently encountered with use of insulin in patients with diabetes.<sup>25</sup> Fructose could increase hepatic glucose uptake and glycogen storage, and reduce peripheral glycemia and insulin levels; this could be beneficial in diabetic patients.<sup>89</sup> This suggests that honey might be a suitable food for diabetics and nondiabetics. However, fructose consumption causes undesirable effects such as hyperinsulinemia, induction of insulin resistance, hypertriglyceridemia, increased weight gain, hepatic *de novo* lipogenesis, and HTN in animal models.<sup>90-94</sup>

Honey contains more than 181 bioactive constituents including free radical scavenging and antioxidant compounds.<sup>27,95</sup> In addition, honey contains arginine and NO metabolites and it increases NO production in animals and human.<sup>37,38</sup> L-Arginine is able to prevent fructose-induced HTN and hyperinsulinemia.<sup>96</sup> Therefore, we have proposed that NO might inhibit fructose-induced hyperinsulinemia after ingestion of honey.<sup>25</sup> Honey compared with dextrose or sucrose decreased insulin levels in normal subjects. The mild effect of honey on PGL and plasma insulin and C-peptide in normal subjects might be due to fructose content, as fructose does not stimulate insulin secretion from pancreatic  $\beta$  cells.<sup>97</sup>

Fructose reduces hyperglycemia in rodent models of diabetes, healthy subjects, and diabetic patients.<sup>98-100</sup> Fructose prolongs gastric emptying and it lowers food intake.<sup>101-103</sup> A low or moderate fructose diet resulted in weight loss in obese subjects.<sup>103</sup> Obese subjects on the moderate fructose diet lost more weight than those on the low fructose diet.<sup>104</sup> However, some studies have found that fructose feeding or consumption at high doses is associated with increased weight gain.<sup>91,94</sup> Fructose increases hepatic glucose phosphorylation via activation of glucokinase, and inhibits glycogenolysis via suppression of phosphorylase.<sup>105,106</sup> Fructose increased hepatic glycogen synthesis in diabetic and nondiabetic rats.<sup>105,107</sup>

TABLE 3. EFFECTS OF VARIOUS SAMPLES OF HONEY ON BLOOD SUGAR IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS

<i>Study</i>	<i>Origin of honey/method of administration</i>	<i>Number of patients</i>	<i>Results</i>
Samanta <i>et al.</i> (1985) <sup>57</sup>	United Kingdom; oral	8 type 1 DM 6 type 2 D	Honey attenuated postprandial glycemic response
Bornet <i>et al.</i> (1985) <sup>61</sup>	Italy; oral	21 type 2 DM	Honey, compared to an isoglucidic amount of bread, has no additional hyperglycemic effect in 21 type 2 diabetic individuals when consumed for breakfast
Katsilambros <i>et al.</i> (1988) <sup>62</sup>	Greece; oral	31 type 2 DM	Hyperglycemia similar to that produced by consuming bread
Agrawal <i>et al.</i> (2007) <sup>63</sup>	India; oral	30 with impaired glucose tolerance test or type 2 DM	Significantly lower PGL after consumption of honey in comparison to the glucose tolerance test. In diabetic patients, the high degree of tolerance to honey was recorded too
Abdulrhman <i>et al.</i> (2011) <sup>64</sup>	Egypt; oral	20 children and adolescents with type 1 DM and 10 healthy children and adolescents	Honey, compared to sucrose, had lower glycemic index and incremental index in both diabetic patients and control
Al-Waili (2004) <sup>53</sup>	United Arab Emirates; oral	12 type 2 DM	Honey compared with dextrose caused a significantly lower rise of PGL after GTT. Honey caused greater elevation of insulin than sucrose did after 30, 120, and 180 min in diabetics
Al-Waili (2003) <sup>14</sup>	United Arab Emirates; inhalation	24 type 2 DM	Honey inhalation was effective in reducing PGL; it could improve glucose tolerance test and elevate plasma insulin and C-peptide in diabetic patients

DM, diabetes mellitus; GTT, glucose tolerance test.

Honey tastes sweeter than sucrose, so it was suggested that a pure natural honey in low doses might be recommended as sources of carbohydrates and even as sweetening agents in place of sucrose to diabetic patients.<sup>25</sup> The effects of honey or its constituents on gastric emptying, insulin secretion, rate of intestinal absorption, prostaglandin inhibition, NO production, fructose transporter, antioxidants level, hepatic glucose uptake, zinc and copper levels, and food intake, and perhaps the synergistic effect of glucose on fructose may contribute to the lowering of glucose levels.<sup>85,101,103,108–109</sup>

#### *Honey and lipids*

In Iran, 48 patients with type 2 DM received oral natural honey intake for eight weeks; honey decreased total cholesterol, low-density lipoprotein-cholesterol (LDL-C), and triacylglycerol, and increased high-density lipoprotein-cholesterol (HDL-C).<sup>110</sup> Another study showed that 70 g of natural honey collected in Iran decreased total cholesterol (3%), LDL-C (5.8%), and triacylglycerol (11%), and in-

creased HDL-C (3.3%) in subjects with normal values and in patients who were overweight or obese.<sup>52</sup>

In New Zealand, rats fed 10% honey increased the HDL-C significantly compared with rats fed 7.9% sucrose or a sugar-free diet.<sup>60</sup> In Germany, among patients who had high cholesterol, LDL-C values did not significantly reduce in males after ingesting a 75-g honey solution for 14 days. However, in women, these values increased in the sugar solution group, but not in that fed honey.<sup>111</sup> It was suggested that although ingesting honey did not reduce LDL-C values, women might benefit from substituting honey for sugar in their diet.<sup>111</sup>

In the United States, a study conducted in rats showed that honey lowered serum concentrations of triacylglycerol compared with diets of equal energy densities. However, there were no significant differences in serum total cholesterol or HDL-C.<sup>112</sup> In Nigeria, a recent study showed that consumption of unrefined Nigerian honey significantly improved lipid profiles and the computed CVD predictive index in male albino rats.<sup>113</sup>

The authors found that a single dose of glucose or artificial honey (consisting of 40 g fructose + 35 g glucose in

250 mL water) increased cholesterol and triacylglycerol; this effect was not observed with natural honey collected in the U.A.E.<sup>53</sup> In this regard, daily consumption of 75 g honey for 15 days decreased total cholesterol (8%), LDL-C (11%), and CRP (75%) in normal and hyperlipidemic subjects.

Natural honey decreased total cholesterol and LDL-C in healthy and hyperlipidemic subjects while artificial honey increased lipids because of the presence of fructose. It was proposed that the difference between the effects of artificial and natural honeys on lipids might be due to the presence of certain substances in natural honey that are able to reduce blood lipids in healthy and hyperlipidemic subjects.<sup>51</sup> Fructose potentiates postprandial lipidemia in both diabetic and nondiabetic subjects and very high intake of sucrose or fructose increased fasting triacylglycerol.<sup>114,115</sup>

In patients with hypercholesterolemia, the formation of the F<sub>2</sub>-isoprostane 8-epi-PGF<sub>2</sub> $\alpha$  is enhanced, which is suppressed by vitamin E supplementation.<sup>116</sup> It has been reported that high doses of B complex vitamin may be useful in lowering blood cholesterol and triacylglycerole levels. Vitamin E reduces atherosclerosis plaque, coronary artery diseases, and myocardial infarction.<sup>117</sup> Many studies showed that ascorbic acid deficiency involved in the development of hypercholesterolemia and atherosclerosis.<sup>118</sup> Antioxidants can modulate the activity and/or the protein levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase (the rate-limiting enzyme of cholesterol biosynthetic pathway).<sup>119</sup> Polyphenols derived from tea were shown to have antioxidative, antithrombogenic, anti-inflammatory, hypotensive, and hypocholesterolemic properties.<sup>120</sup> Further, polyphenols have vasodilating effects, and they can improve the lipid profile and lessen the oxidation of LDL.<sup>121</sup> The effects of honey on lipid profile might be related to NO, antioxidants, vitamin E, prostaglandins, and antioxidant properties.<sup>116–123</sup> However, the exact mechanisms through which honey exerts its effect on lipid values are not well identified.

#### *Honey and blood pressure*

It is well known that HTN is one of the major risk factors for cardiovascular and renal diseases. Most of patients fail to maintain goal blood pressure despite using various antihypertensive modalities.

Administration of Malaysian tualang honey for 3 weeks in streptozotocine-induced diabetic spontaneously hypertensive rats resulted in reduction in systolic blood pressure.<sup>124</sup> This effect was mediated via amelioration of oxidative stress in the kidney.<sup>125</sup> The authors found that systolic and diastolic blood pressure was reduced by honey inhalation in hypertensive patients; significant changes were obtained at 60 and 120 min after inhalation.<sup>14</sup>

Oxidative stress and free radicals are involved in the pathogenesis and/or maintenance of elevated blood pressure in HTN.<sup>126–129</sup> In addition, there is strong evidence of a close relationship between NO deficiency and development of HTN.<sup>130</sup> Further, chronic NO inhibition with L-nitro-arginine methyl ester, an antagonist for L-arginine, causes salt-sensitive HTN and the development of renal injury.<sup>131</sup>

Therefore, honey might mitigate HTN by its antioxidant constituents and its ability to increase NO. Further studies are needed to explore the exact mechanism of action.

#### *Honey and CRP*

CRP is an acute phase protein that is produced by hepatocytes in response to inflammatory cytokines in the body. CRP serves as a biomarker of CVD risk and inflammation. Increased levels of CRP are correlated with cardiac risk factors such as type 2 diabetes mellitus, obesity, and smoking.<sup>132,133</sup> CRP functions as a pro-atherosclerotic factor too.<sup>134</sup> In the previous study, oral ingestion of honey reduced CRP.<sup>53</sup> Further, daily ingestion of 70 g of natural honey caused 3.2% reduction in CRP in subjects with normal values and in patients with elevated variables in obese and overweight individuals.<sup>52</sup> However, in the United States, a study conducted in rats showed that there were no significant differences in CRP in rats fed honey or diets of equal energy densities.<sup>113</sup>

It has been shown that antioxidants and vitamin E reduce the concentration of CRP.<sup>135,136</sup> An increased intake of foods rich in polyphenolic compounds is inversely associated with CRP concentrations.<sup>132,133,137–138</sup> Honey contains many antioxidants. Therefore, honey might reduce CRP by its antioxidant properties.

#### *Honey and NO*

NO is a gaseous signaling molecule, which plays an important role in a variety of human biological processes. It is synthesized by NO synthase; neuronal, inducible and endothelial. NO plays an important role in vasodilation via the relaxation of vascular smooth muscle, in increasing circulation in the body and in the protection against the onset and progression of CVD. The cardioprotective roles of NO include regulation of blood pressure and vascular tone, vasodilatation, prevention of smooth muscle cell proliferation, inhibition of platelet aggregation, and leukocyte activation.<sup>139–141</sup> Patients with atherosclerosis, DM, or HTN show impaired NO pathways.<sup>142</sup>

We have found that honey contains NO end products.<sup>37</sup> In addition, honey increases NO end products in various biological fluids such as urine, saliva, and plasma.<sup>38</sup> Intravenous honey increased NO end product in plasma and urine.<sup>38</sup>

Tualang honey inhibited UVB-induced inflammatory cytokines and inducible NO synthase protein expression. Intravenous honey reduced cytokine (tumor necrosis factor- $\alpha$ , and interleukins 1 $\beta$  and 10) and NO levels and increased heme oxygenase-1 levels in rats with LPS-induced endotoxemia.<sup>143</sup>

In inflammatory processes, it was found that honey inhibits NO and prostaglandins.<sup>143–146</sup> In this situation, honey might inhibit inducible harmful NO. Inhibition of inducible nitric oxide synthase (iNOS) activity produces a marked anti-inflammatory effect in acute and chronic inflammation.<sup>147</sup> Further, the anti-inflammatory effect of honey might be due to the presence of polyphenolic compounds.<sup>148,149</sup>

Polyphenolic compounds have potent antioxidative activities that might scavenge iNO.<sup>150</sup>

In this regard, it has been demonstrated that many plant polyphenolic compounds could modulate NO levels and/or actions.<sup>151,152</sup> Therefore, honey could prevent or ameliorate CVD with upregulation of NO. More studies are required to explore this important field.

#### *Honey and prostaglandins*

It is well documented that prostaglandins are mediators of inflammation and pain. Prostaglandins reduce immunity and play a critical role in cancer development.<sup>153,154</sup>

The main vasoactive factors released by endothelial cells are NO and prostaglandins.<sup>155,156</sup> PGI<sub>2</sub> and PGD<sub>2</sub> are vasodilators, whereas PGH<sub>2</sub>, PGF<sub>2</sub>α, and thromboxane A<sub>2</sub> are vasoconstrictors and platelet aggregation inducers.<sup>157–159</sup> PGE<sub>2</sub> can induce vasodilation or vasoconstriction.<sup>160,161</sup> Interaction between PGF<sub>2</sub>α and its receptor triggers potent vasoconstriction.<sup>162,163</sup> PGF<sub>2</sub>α promotes cardiac hypertrophy.<sup>164</sup> Studies have shown that serum levels of 8-iso-PGF<sub>2</sub>-α increased in obesity, DM, arthritis, and CVD.<sup>165,166</sup> Thromboxane A<sub>2</sub> elicits platelet aggregation and vascular smooth muscle contraction.<sup>167</sup> The production of thromboxane A<sub>2</sub> is increased in patients with unstable angina, infarction, cerebral vasospasm, and pregnancy-induced HTN.<sup>168,169</sup>

Gelam honey was also shown to depress production of PGE<sub>2</sub> and NO on exudates of rat's paw induced with carageenan and lipopolysaccharide.<sup>145</sup> It was found that tualang honey inhibited UVB-induced COX-2 expression and PGE<sub>2</sub> production.<sup>146</sup>

The authors have reported for the first time that oral honey could reduce plasma and urinary PGE<sub>2</sub>, PGF<sub>2</sub>-α, and thromboxane B<sub>2</sub>.<sup>75</sup> Its inhibitory effect was increased with time. The site of actions could be either at COX-1 or COX-2, or both. In addition, it was found that artificial honey made of glucose and fructose, increased prostaglandin concentrations.<sup>170</sup>

Hydrogen peroxide induces PGE<sub>2</sub> production by forming ROS that oxidizes phospholipids in the membrane.<sup>171</sup> Gelam and Nenas monofloral honeys showed significant anti-inflammatory effects on inflammation induced-HT29 cells by decreasing the level of PGE<sub>2</sub> of cells as effective as indomethacin.<sup>172</sup> Polyphenols can reduce serum 8-Iso PGF<sub>2</sub>α.<sup>173</sup> Therefore, natural honey might contain raw materials that are capable of inhibiting prostaglandin synthesis.<sup>75</sup> Obviously, it appears that honey has anti-inflammatory properties that make it a suitable nutrient to be used in acute or chronic inflammatory conditions.<sup>75</sup>

#### *Honey and homocysteine*

Homocysteine, an amino acid that is produced in the human body, impairs the generation and decreases bioavailability of NO. Individuals with lower homocysteine have lower rate of CVD.<sup>174</sup> Homocysteine is an important risk factor for cancer and CVD and increases in its concentrations are associated with an increased risk for ne-

phropathy and proliferative retinopathy.<sup>175,176</sup> Honey decreases homocysteine level by 8% in normal subjects after 15 days of consumption. Vitamin C protects LDL-C from homocysteine-mediated oxidation.<sup>177</sup> In healthy and diabetic subjects homocysteine inhibited platelet NO production.<sup>178</sup> We found that honey increased the NO concentration and antioxidant levels in humans.<sup>24,37,38,75,174</sup> This might explain, in part, the hypohomocysteinemic effects of honey.

#### *Honey and obesity*

Obesity is a global epidemic.<sup>179</sup> It is associated with CVD, type 2 DM, HTN, cancer, and sleep apnea. Obesity is an independent risk factor for CVD.<sup>180</sup> Abnormal endothelial function as a results of decreased NO is found in obesity.<sup>181</sup> HTN is more common in obese than in lean individuals.<sup>182</sup> A strong correlation was demonstrated between obesity and IL-6 and CRP levels. In general, obesity is a low-grade systemic inflammation. Diet modulation, physical activity, pharmacotherapy, and surgery are recommended as part of the management of obesity.<sup>183</sup> Weight loss improves or prevents many of the obesity-related risk factors for CVD.<sup>183</sup>

In the United States, a study conducted in rats showed that honey lowered serum concentrations of leptin and reduced weight gain and adiposity compared with diets of equal energy densities.<sup>112</sup> In New Zealand, a study was conducted in rats to determine whether 10% honey and 7.9% sucrose would have differential effects on weight gain during 52 weeks feeding. Overall weight gain and body fat levels were significantly higher in sucrose-fed rats than those fed honey or a sugar-free diet.<sup>60</sup> In New Zealand, despite a similar food intake, the percentage weight gain was significantly lower in honey-fed rats than those fed sucrose or mixed sugars.<sup>184</sup>

In the University of Wyoming, Laramie, a double-blind, randomly assigned study evaluated whether the meal-induced responses of ghrelin and peptide YY (3–36) and/or meal-induced thermogenesis differ following a honey-versus a sucrose-containing meal. It was found that honey delayed the postprandial ghrelin response, enhanced the total peptide YY response, and blunted the glucose response compared with consumption of the sucrose-containing meal.<sup>185</sup> In Iran, daily ingestion of 70 g of natural honey caused reduction in body weight (1.3%), body fat (1.1%) in overweight and obese individuals.<sup>52</sup>

Honey does not cause a significant reduction in PGL 3 h after consumption compared with sucrose or D-glucose.<sup>51,53</sup> This might reduce hunger and food intake.

#### *Antioxidative agents*

In animal models and clinical studies, DM, hypercholesterolemia, or HTN are associated with increased vascular free radicals generation.<sup>186–190</sup> CVD is a disease of oxidative damage and inflammation, which results in elevation of proinflammatory mediators and low NO bioavailability. Increased free radicals cause a functional inactivation NO due to the reaction with superoxide anion. A cross-sectional



TABLE 4. EFFECTS OF HONEY ON COMMON CARDIOVASCULAR RISK FACTORS

Variables	Effect of honey	Possible mechanism of action
Blood sugar	Reduces blood sugar in normal individuals and in patients with diabetes	Flavonoids and antioxidants <sup>68-71</sup> Increases copper and zinc <sup>73,74</sup> Inhibition of prostaglandin <sup>75,76</sup> Elevation of NO <sup>37,38</sup> Glycemic carbohydrates <sup>78,79</sup> Hydrogen peroxide <sup>80</sup> Oligosaccharides <sup>81-83</sup> Fructose <sup>98-107</sup>
HTN	Lowers blood pressure	Antioxidant constituents and increment of NO <sup>24,110</sup>
Lipid profile	Decreases total cholesterol, LDL-cholesterol, and triacylglycerol, and increases HDL-cholesterol in healthy and hyperlipidemic subjects	Antioxidants, polyphenols, and vitamin content, elevation of NO, and suppression of prostaglandins <sup>124-131</sup>
CRP	Decreases CRP	Antioxidants, polyphenols, and vitamin E content <sup>132,133,135-139</sup>
Homocysteine	Decreases homocysteine	Vitamin C content <sup>177</sup> NO production <sup>178</sup>
Body weight	Decreases body weight in normal, overweight and obese individuals	Honey delays the postprandial ghrelin response, enhances the total PYY response, and blunts the glucose response <sup>184</sup> Honey reduces hunger and food intake <sup>51,53</sup>

CRP, C-reactive protein; HDL, high-density lipoprotein; HTN, hypertension; LDL, low-density lipoprotein; PYY, peptide YY.

study performed on 71 patients clinically diagnosed with CVD showed a significant reduction in antioxidant status (enzymatic and nonenzymatic) with a concomitant increase in the concentrations of lipid peroxidation products.<sup>191</sup>

Polyphenols and flavonoids inhibit LDL oxidation and platelet aggregation; reduce atherosclerotic lesion formation; reduce blood pressure; improve endothelial function; and decrease vascular cell adhesion molecule expression, iNO generation, and inflammatory responses.<sup>192-204</sup> Flavonoid intake reduces risk of CVD.<sup>205</sup> Flavonoids have antithrombotic, anti-ischemic, antioxidant, and vasorelaxant properties.<sup>206</sup> They are scavengers of superoxide anions, singlet oxygen, and lipid peroxy-radicals and they prevent LDL-C oxidation.<sup>190,207,208</sup> The beneficial effect of polyphenols on CVD is attributed to modulation of NO bioavailability to the endothelium.<sup>209,210</sup>

$\beta$ -carotenoids have anti-inflammatory activity in the vasculature and this might explain the protective effects of carotenoid-rich diets against CVD risk.<sup>211</sup>  $\beta$ -carotene affect endothelial response to TNF- $\alpha$  and reduce nitro-oxidative stress.<sup>211</sup>

Improvement of endothelial function and the antihypertensive effects of quercetin might be mediated by enhanced eNOS activity and decreased NADPH oxidase-mediated superoxide anion generation associated with reduced p47 expression.<sup>212</sup>

Various types of honey contain many antioxidants and antioxidant enzymes including vitamins E and C, ascorbic acid, phenolic acids, flavonoids, carotenoid derivatives, organic acids, Maillard reaction products, glucose oxidase, catalase, and glutathione peroxidase.<sup>213-216</sup>

The polyphenols in honey are caffeic acid, caffeic acid phenyl ester, chrysin, galangin, quercetin, acacetin, kaempferol, pinocembrin, pinobanksin, and apigenin.<sup>217</sup> Natural honey protects normal rats from the incidence of epinephrine-induced cardiac disorders and vasomotor dysfunction.<sup>218</sup>

The beneficial effect of honey on CVD might be attributed to its antioxidative and anti-inflammatory properties, increment of NO production, and improvement of blood sugar and blood pressure (Table 4).<sup>24,37,38,51,53,68-71,73-76,78-83,98-107,110,124-133,135-139,177,178,184</sup>

### CONCLUSION

Natural honey has many biological activities besides its antimicrobial activity (Figure 1). Honey ingestion increases blood vitamin C level,  $\beta$ -carotene, uric acid, glutathione reductase, copper, zinc, NO end products, and decreases PGL, CRP, homocysteine, and plasma prostaglandin E2, F2- $\alpha$ , and thromboxane B2 concentrations. Moreover, honey




FIG. 1. Biological effects of honey on blood glucose, lipids and inflammatory markers.

improves lipid profiles and modulates C-peptide and insulin secretion. Honey has powerful antioxidative activity and its ingestion increases antioxidative materials. Honey appears to have many effects on various metabolic parameters. Its contents and effects on metabolic parameters might result in beneficial effects seen in patients with DM, HTN, and CVD. From studies reviews, honey appears to be a powerful natural biological syrup that may be recommended to be used in healthy individuals, and in patients with DM, HTN, and CVD.

### ACKNOWLEDGMENT

The authors are thankful to National Plan for Science and Technology (NPST) program of King Saud University, Project No. 11-AGR1748-02 for financial support.

### AUTHOR DISCLOSURE STATEMENT

The authors declared that there is no conflict of interest regarding the publication of this article.

### REFERENCES

1. WHO: Cardiovascular diseases (CVDs). [www.who.int/mediacentre/factsheets/fs317/en/index.html](http://www.who.int/mediacentre/factsheets/fs317/en/index.html) (accessed March 2013).
2. Al-Waili N, Salom K: Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following caesarean sections and hysterectomies. *Eur J Med Res* 1999;4:126–130.
3. Al-Waili NS, Salom K, Butler G, Al Ghamdi AA: Honey and microbial infections: a review supporting the use of honey for microbial control. *J Med Food* 2011;14:1079–1096.
4. Al-Waili N, Salom K, Al-Ghamdi A: Honey for wound healing, ulcers, and burns; data supporting its use in clinical practice. *ScientificWorldJournal* 2011;11:766–787.
5. Othman N: Honey and cancer: sustainable inverse relationship particularly for developing nations-a review. *Evid Based Complement Alternat Med* 2012;2012:41040.
6. Parmar J, Hunjan P, Brown A, Telfer M: Honey dressing use for the management of split thickness skin graft donor sites: a technical note. *Br J Oral Maxillofac Surg* 2013;1:e40–e41.
7. Erejuwa O, Sulaiman SA, Wahab MS: Hepatoprotective effect of tualang honey supplementation in streptozotocin-induced diabetic rats. *Int J Appl Res Nat Prod* 2012;4:37–41.
8. Erejuwa O, Gurtu S, Sulaiman SA: Hypoglycemic and antioxidant effects of honey supplementation in streptozotocin-induced diabetic rats. *Int J Vitam Nutr Res* 2010;80:74–82.
9. Erejuwa O, Sulaiman SA, Wahab MS: Antioxidant protective effect of glibenclamide and metformin in combination with honey in pancreas of streptozotocin-induced diabetic rats. *Int J Mol Sci* 2010;11:2056–2066.
10. Erejuwa O, Sulaiman SA, Wahab MS: Comparison of antioxidant effects of honey, glibenclamide, metformin, and their combinations in the kidneys of streptozotocin-induced diabetic rats. *Int J Mol Sci* 2011;12:829–843.
11. Erejuwa O, Sulaiman SA, Wahab MS: Antioxidant protection of Malaysian tualang honey in pancreas of normal and streptozotocin-induced diabetic rats. *Ann Endocrinol (Paris)* 2010;71:291–296.
12. Beretta G, Orioli M, Facino RM: Antioxidant and radical scavenging activity of honey in endothelial cell cultures (EA.hy926). *Planta Med* 2007;73:1182–1189.
13. Beretta G, Granata P, Ferrero M: Standardization of antioxidant properties of honey by a combination of spectrophotometric/fluorimetric assays and chemometrics. *Anal Chim Acta* 2005;533:185–191.
14. Al-Waili N: Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distilled water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate. *Eur J Med Res* 2003;8:295–303.
15. AL-Waili N, Al-Ghamdi A, Ansari M, Al-Attal Y, Salom K: Synergistic effects of honey and propolis toward drug multi-resistant *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans* isolates in single and polymicrobial cultures. *Int J Med Res* 2012;9:793–800.
16. Khalil MI, Sulaiman SA: The potential role of honey and its polyphenols in preventing heart diseases: a review. *Afr J Tradit Complement Altern Med* 2010;7:315–321.
17. Buldini L, Cavalli S, Mevoli A, Sharma J: Ion chromatographic and voltammetric determination of heavy and transition metals in honey. *Food Chem* 2001;73:487–495.
18. Muñoz E, Palmero S: Determination of heavy metals in honey by potentiometric stripping analysis and using a continuous flow methodology. *Food Chem* 2006;94:478–483.
19. Ouchemoukh S, Louaileche H, Schweizer P: Physicochemical characteristics and pollen spectrum of some Algerian honeys. *Food Control* 2007;18:52–58.
20. Saxena S, Gautam S, Sharma A: Physical, biochemical and antioxidant properties of Indian honeys. *Food Chem* 2010;118:391–397.
21. Bertoneclj J, Doberšek U, Jamnik M, Golob T: Evaluation of the phenolic content, antioxidant activity, and colour of Slovenian honey. *Food Chem* 2007;105:822–828.
22. Aljadi A, Kamaruddin M: Evaluation of the phenolic contents and antioxidant capacities of two Malaysian floral honeys. *Food Chem* 2004;85:513–518.
23. Islam A, Islam N, Moniruzzaman M: Physicochemical and antioxidant properties of Bangladeshi honeys stored for more than one year. *BMC Complement Altern Med* 2012;12:177.
24. Anklam E: A review of the analytical methods to determine the geographical and botanical origin of honey. *Food Chem* 1998;63:549–562.
25. Al-Waili NS: Effects of daily consumption of honey solution on hematological indices and blood levels of minerals and enzymes in normal individuals. *J Med Food* 2003;6:135–140.
26. Ensminger A, Ensminger M, Konlande J, Robson J: *Food and Nutrition Encyclopedia*. Pegus Press, Clovis, CA, USA, 1983.
27. Bogdanov S, Jurendic T, Sieber R, Gallmann P: Honey for nutrition and health: a review. *J Am Coll Nutr* 2008;27:677–689.
28. Riethop M, Subers M, Kushnir I: *Composition of American Honeys*. U.S. Department of Agriculture Technical Bulletin 1261, Washington, DC, 1962; p. 124.
29. Baroni V, Chiabrando A, Costa C, Fagundes A, Wunderlin A: Development of a competitive ELISA for the evaluation of sunflower pollen in honey samples. *J Agric Food Chem* 2004;52:7222–7226.
30. White J, Doner L: Honey Composition and properties. [www.beesource.com/resources/usda/honey-composition-and-properties](http://www.beesource.com/resources/usda/honey-composition-and-properties) (accessed October 2013).
31. Nagai T, Inoue R, Kanamori N, Suzuki N, Nagashima T: Characterization of honey from different floral sources. Its

- functional properties and effects of honey species on storage of meat. *Food Chem* 2006;97:256–262.
32. Baroni V, Nores L, Díaz P, Chiabrando A, Fassano P, Costa C, Wunderlin A: Determination of volatile organic compound patterns characteristic of five unifloral honey by solid-phase microextraction-gas chromatography-mass spectrometry coupled to chemometrics. *J Agric Food Chem* 2006;54:7235–7241.
33. Baroni V, Chiabrando A, Costa C, Wunderlin A: Assessment of the floral origin of honey by SDS–PAGE immunoblot techniques. *J Agric Food Chem* 2002;50:1362–1367.
34. Al-Mamary M, Al-Meerri A, Al-Habori M: Antioxidant activities and total phenolics of different types of honey. *Nutr Res* 2002;22:1041–1047.
35. Gheldof N, Engeseth NJ: Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of *in vitro* lipoprotein oxidation in human serum samples. *J Agric Food Chem* 2002;50:3050–3055.
36. Tomás-Barberán A, Martos I, Ferreres F, Radovic S, Anklam E: HPLC flavonoid profiles as markers for the botanical origin of European unifloral honeys. *J Sci Food Agric* 2001;81:485–496.
37. Al-Waili NS, Boni NS: Honey increased saliva, plasma, and urine content of total nitrite concentrations in normal individuals. *J Med Food* 2004;7:377–380.
38. Al-Waili NS: Identification of nitric oxide metabolites in various honeys: effects of intravenous honey on plasma and urinary nitric oxide metabolites concentrations. *J Med Food* 2003;6:359–364.
39. Nozal J, Bernal L, Toribio L, Alamo M, Diego C, Tapia J: The use of carbohydrate profiles and chemometrics in the characterization of natural honeys of identical geographical origin. *J Agric Food Chem* 2005;53:3095–3100.
40. Fernández-Torres R, Pérez-Bernal L, Bello-López A, Callejón-Mochón M, Jiménez-Sánchez C, Guiraúm-Pérez A: Mineral content and botanical origin of Spanish honeys. *Talanta* 2005;65:686–691.
41. Ruoff K, Luginbuhl W, Kunzli R, Bogdanov S, Bosset O, Von Der Ohe K, Von Der Ohe W, Amado R: Authentication of the botanical and geographical origin of honey by front-face fluorescence spectroscopy. *J Agric Food Chem* 2006;54:6858–6866.
42. Beretta G, Gelmini F, Lodi V, Piazzalunga A, Maffei Facino R: Profile of nitric oxide (NO) metabolites (nitrate, nitrite and N-nitroso groups) in honeys of different botanical origins: nitrate accumulation as index of origin, quality and of therapeutic opportunities. *J Pharm Biomed Anal* 2010;53:343–349.
43. Bogdanov S: Honey quality, methods of analysis, and international regulatory standards: review of the work of the international honey commission. *Mitt Gebiete Lebensm Hyg* 1999;90:108–125.
44. Korta E, Bakkali A, Berrueta A, Gallo B, Vicente F: Study of an accelerated solvent extraction procedure for the determination of acaricide residues in honey by high-performance liquid chromatography-diode array detector. *J Food Prot* 2002;65:161–166.
45. Grembecka M, Szefer P: Evaluation of honeys and bee products quality based on their mineral composition using multivariate techniques. *Environ Monit Assess* 2013;185:4033–4047.
46. Robert S, Ismail A: Two varieties of honey that are available in Malaysia gave intermediate glycemic index values when tested among healthy individuals Biomed Pap. *Med Fac Univ Palacky Olomouc Czech Repub* 2009;153:145–147.
47. Deibert P, König D, Kloock B, Groenefeld M, Berg A: Glycaemic and insulinaemic properties of some German honey varieties. *Eur J Clin Nutr* 2010;64:762–764.
48. Münstedt K, Sheybani B, Hauenschild A, Brüggmann D, Bretzel RG, Winter D: Effects of basswood honey, honey-comparable glucose-fructose solution, and oral glucose tolerance test solution on serum insulin, glucose, and C-peptide concentrations in healthy subjects. *J Med Food* 2008;11:424–428.
49. Ischayek JI, Kern M: US honeys varying in glucose and fructose content elicit similar glycemic indexes. *J Am Diet Assoc* 2006;106:1260–1262.
50. Shambaugh P, Worthington V, Herbert J: Differential effects of honey, sucrose, and fructose on blood sugar levels. *J Manipulative Physiol Ther* 1990;13:322–325.
51. Ahmad A, Azim M, Msaik M, Khan R: Natural honey modulates physiological glycemic response compared to simulated honey and D-glucose. *J Food Sci* 2008;73:H165–H167.
52. Yaghoobi N, Al-Waili N, Ghayour-Mobarhan M, Parizadeh S, Abasalti Z, Yaghoobi Z, Yaghoobi F, Esmaeili H, Kazemi-Bajestani S, Aghasizadeh R, Saloom K, Ferns G: Natural honey and cardiovascular risk factors; effects on blood glucose, cholesterol, triacylglycerole, CRP, and body weight compared with sucrose. *ScientificWorldJournal* 2008;8:463–469.
53. Al-Waili N: Natural honey lowers plasma glucose, C-reactive protein, homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with dextrose and sucrose. *J Med Food* 2004;7:100–107.
54. Al-Waili NS, Saloom KY, Akmal M, Al-Waili F, Al-Waili TN, Al-Waili AN, Ali A: Honey ameliorates influence of hemorrhage and food restriction on renal and hepatic functions, and hematological and biochemical variables. *Int J Food Sci Nutr* 2006;57:353–362.
55. Al-Waili NS, Salom KY, Al-Waili TN, Al-Waili AN, Akmal M, Al-Waili FS, Al-Waili HN: Influence of various diet regimens on deterioration of hepatic function and hematological parameters following carbon tetrachloride: a potential protective role of natural honey. *Nat Prod Res* 2006;20:1258–1264.
56. Al-Waili NS: Intravenous and intrapulmonary administration of honey solution to healthy sheep: effects on blood sugar, renal and liver function tests, bone marrow function, lipid profile, and carbon tetrachloride-induced liver injury. *J Med Food* 2003;6:231–247.
57. Samanta A, Burden AC, Jones GR: Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycaemic and peak incremental indices. *Diabet Med* 1985;2:371–373.
58. Erejuwa O, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, Gurtu S: Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. *Int J Biol Sci* 2011;7:244–252.
59. Akhtar MS, Khan MS: Glycaemic responses to three different honeys given to normal and alloxan-diabetic rabbits. *J Pak Med Assoc* 1989;39:107–113.
60. Chepulis L, Starkey N: The long-term effects of feeding honey compared with sucrose and a sugar-free diet on weight gain, lipid profiles, and DEXA measurements in rats. *J Food Sci* 2008;73:H1–H7.



61. Bornet F, Haardt M, Costagliola D, Blayo A, Slama G: Sucrose or honey at breakfast have no additional acute hyperglycaemic effect over an isoglucidic amount of bread in Type 2 diabetic patients. *Diabetologia* 1985;28:213–217.
62. Katsilambros N, Philippides P, Touliatou A, Georgakopoulos K, Kofotzouli L, Frangaki D, Siskoudis P, Marangos M, Sfikakis P: Metabolic effects of honey (alone or combined with other foods) in type II diabetics. *Acta Diabetol Lat* 1988; 25:197–203.
63. Agrawal OP, Pachauri A, Yadav H, Urmila J, Goswamy HM, Chapperwal A, Bisen PS, Prasad GB: Subjects with impaired glucose tolerance exhibit a high degree of tolerance to honey. *J Med Food* 2007;10:473–872.
64. Abdulrhman M, El-Hefnawy M, Hussein R, El-Goud AA: The glycemic and peak incremental indices of honey, sucrose and glucose in patients with type 1 diabetes mellitus: effects on C-peptide level—a pilot study. *Acta Diabetol* 2011;48:89–94.
65. Ionescu-Tirgoviste C, Popa E, Sintu E, Mihalache N, Chejra D, Mincu I: Blood glucose and plasma insulin responses to various carbohydrates in type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1983;24:80–84.
66. Baltali M, Kokmaz M, Kiziltan H: Association between postprandial hyperinsulinemia and coronary artery among non-diabetic women: a case control study. *Int J Cardiol* 2003;88:215–221.
67. Wang X, Andrae L, Engeseth N: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 2002;15:2067–2072.
68. Lee Y, Lee S, Lee H, Kim B, Ohuchi K, Shin KH: Inhibitory effects of isorhamnetin-3-O-beta-D-glucoside from *Salicornia herbacea* on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. *Biol Pharm Bull* 2005;28:916–918.
69. Fang X, Gao J, Zhu D: Kaempferol and quercetin isolated from *Euonymus alatus* improve glucose uptake of 3T3-L1 cells without adipogenesis activity. *Life Sci* 2008;82:615–622.
70. Kobori M, Masumoto S, Akimoto Y, Takahashi Y: Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. *Mol Nutr Food Res* 2009;53:859–868.
71. Kwon O, Eck P, Chen S, Corpe C, Lee J, Kruhlak M, Levine M: Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. *FASEB J* 2007;21:366–377.
72. Viuda-Martos M, Ruiz-Navajas Y, Fernández-López J, Pérez-Alvarez J: Functional properties of honey, propolis, and royal jelly. *J Food Sci* 2008;73:R117–R124.
73. Song M, Hwang I, Rosenthal M, Harris D, Yamaguchi D, Yi I, Go V: Antidiabetic action of arachidonic acid and zinc in genetically diabetic Goto-Kakizaki rats. *Metabolism* 2003;52:7–12.
74. Sitasawad S, Deshpande M, Katdare M, Tirth S, Parab P: Beneficial effect of supplementation with copper sulfate on STZ-diabetic mice (IDDM). *Diabetes Res Clin Pract* 2001;52:72–84.
75. Al-Waili NS, Boni NS: Natural honey lowers plasma prostaglandin concentrations in normal individuals. *J Med Food* 2003; 6:129–133.
76. Cheng H, Straub G, Sharp G: Protein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin, and PGE<sub>2</sub>. *Am J Physiol Endocrinol Metabol* 2003;285:E287–E294.
77. Smukler S, Tang L, Wheeler M, Salapatek A: Exogenous nitric oxide and endogenous glucose-stimulated  $\beta$ -cell nitric oxide augment insulin release. *Diabetes* 2002;51:3450–3460.
78. Southgate D: Digestion and metabolism of sugars. *Am J Clin Nutr* 1995;62:203S–211S.
79. Vosloo M: Some factors affecting the digestion of glycaemic carbohydrates and the blood glucose response. *J Fam Ecol Consum Sci* 2005;33:1–9.
80. Hayes G, Lockwood H: Role of insulin receptor phosphorylation in the insulinomimetic effects of hydrogen peroxide. *Proc Nat Acad Sci USA* 1987;84:8115–8119.
81. Erejuwa O, Sulaiman SA, Wahab MS: Oligosaccharides might contribute to the antidiabetic effect of honey: a review of the literature. *Molecules* 2012;17:248–266.
82. Sanz ML, Gonzalez M, Lorenzo C: Carbohydrate composition and physicochemical properties of artisanal honeys from Madrid (Spain): occurrence of *Echium* sp. honey. *J Sci Food Agric* 2004;84:1577–1584.
83. Munstedt K, Bohme M, Hauenschild A: Consumption of rapeseed honey leads to higher serum fructose levels compared with analogue glucose/fructose solutions. *Eur J Clin Nutr* 2011;65:77–80.
84. Kashimura J, Nagai Y: Inhibitory effect of palatinose on glucose absorption in everted rat gut. *J Nutr Sci Vitaminol (Tokyo)* 2007;53:87–89.
85. Lina BA, Jonker D, Koziarowski G: Isomaltulose (Palatinose): a review of biological and toxicological studies. *Food Chem Toxicol* 2002;40:1375–1381.
86. Cani PD, Neyrinck AM, Fava F: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia* 2007;50:2374–2383.
87. Wei Y, Bizeau M, Pagliassotti MJ: An acute increase in fructose concentration increases hepatic glucose-6-phosphatase mRNA via mechanisms that are independent of glycogen synthase kinase-3 in rats. *J Nutr* 2004;134:545–551.
88. Gabriely H, Hawkins M, Vilcu C: Fructose amplifies counter-regulatory responses to hypoglycemia in humans. *Diabetes* 2002;51:893–900.
89. Watford M: Small amounts of dietary fructose dramatically increase hepatic glucose uptake. *Nutr Rev* 2002;60:253–257.
90. Martinez F, Rizza R, Romero J: High fructose feeding elicit insulin resistance, hypertension and hyperinsulinemia in normal dogs. *Hypertension* 1994;23:456–463.
91. Meirelles CJ, Oliveira LA, Jordao AA: Metabolic effects of the ingestion of different fructose sources in rats. *Exp Clin Endocrinol Diabetes* 2011;119:218–220.
92. Malik V, Schulze M, Hu F: Intake of sugar-sweetened beverages and weight gain: a systematic review. *Am J Clin Nutr* 2006;84:274–288.
93. Huynh M, Luiken JJ, Coumans W: Dietary fructose during the suckling period increases body weight and fatty acid uptake into skeletal muscle in adult rats. *Obesity (Silver Spring)* 2008;16: 1755–1762.
94. Bocarsly ME, Powell ES, Avena NM: High-fructose corn syrup causes characteristics of obesity in rats: increased body weight, body fat and triglyceride levels. *Pharmacol Biochem Behav* 2010;97:101–106.
95. Gheldof N, Wang XH, Engeseth NJ: Identification and quantification of antioxidant components of honeys from various floral sources. *J Agric Food Chem* 2002;50:5870–5877.
96. Tay A, Ozcelikay A, Altan V: Effects of L-arginine on blood pressure and metabolic changes in fructose-hypertensive rats. *Am J Hypertens* 2002;15:72–77.



97. Elliott S, Keim N, Stern J: Fructose, weight gain and the insulin resistance syndrome. *Am J Clin Nutr* 2002;76:911–922.
98. Vaisman N, Niv E, Izkhakov Y: Catalytic amounts of fructose may improve glucose tolerance in subjects with uncontrolled non-insulin-dependent diabetes. *Clin Nutr* 2006;25:617–621.
99. Stanhope K, Griffen S, Bremer A: Metabolic responses to prolonged consumption of glucose- and fructose-sweetened beverages are not associated with postprandial or 24-h glucose and insulin excursions. *Am J Clin Nutr* 2011;94:112–119.
100. Kwon S, Kim YJ, Kim MK: Effect of fructose or sucrose feeding with different levels on oral glucose tolerance test in normal and type 2 diabetic rats. *Nutr Res Pract* 2008;2:252–258.
101. Moran TH, McHugh PR: Distinctions among three sugars in their effects on gastric emptying and satiety. *Am J Physiol* 1981;241:R25–R30.
102. Kellett GL, Brot-Laroche E, Mace OJ: Sugar absorption in the intestine: the role of GLUT2. *Annu Rev Nutr* 2008;28:35–54.
103. Thibault L: Dietary carbohydrates: effects on self-selection, plasma glucose and insulin, and brain indoleaminergic systems in rat. *Appetite* 1994;23:275–286.
104. Madero M, Arriaga JC, Jalal D: The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial. *Metabolism* 2011;60:1551–1559.
105. Van Schaftingen E, Davies DR: Fructose administration stimulates glucose phosphorylation in the livers of anesthetized rats. *FASEB J* 1991;5:326–330.
106. Youn JH, Kaslow HR, Bergman RN: Fructose effect to suppress hepatic glycogen degradation. *J Biol Chem* 1987;262:11470–11477.
107. Ciudad CJ, Carabaza A, Guinovart JJ: Glycogen synthesis from glucose and fructose in hepatocytes from diabetic rats. *Arch Biochem Biophys* 1988;267:437–447.
108. Riby JE, Fujisawa T, Kretchmer N: Fructose absorption. *Am J Clin Nutr* 1993;58:748S–753S.
109. Ushijima K, Riby JE, Fujisawa T: Absorption of fructose by isolated small intestine of rats is via a specific saturable carrier in the absence of glucose and by the disaccharidase-related transport system in the presence of glucose. *J Nutr* 1995;125:2156–2164.
110. Bahrami M, Ataie-Jafari A, Hosseini S, Foruzanfar MH, Rahmani M, Pajouhi M: Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. *Int J Food Sci Nutr* 2009;60:618–626.
111. Münstedt K, Hoffmann S, Hauenschild A, Bülte M, von Georgi R, Hackethal A: Effect of honey on serum cholesterol and lipid values. *J Med Food* 2009;12:624–628.
112. Nemoseck TM, Carmody EG, Furchner-Evanson A, Gleason M, Li A, Potter H, Rezende LM, Lane KJ, Kern M: Honey promotes lower weight gain, adiposity, and triglycerides than sucrose in rats. *Nutr Res* 2011;31:55–60.
113. Alagwu EA, Okwara JE, Nneli RO, Osim EE: Effect of honey intake on serum cholesterol, triglycerides and lipoprotein levels in albino rats and potential benefits on risks of coronary heart disease. *Niger J Physiol Sci* 2011;26:161–165.
114. Abraha A, Humphreys S, Clark M: Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. *Br J Nutr* 1998;80:169–175.
115. Truswell A: Food carbohydrates and plasma lipids—an update. *Am J Clin Nutr* 1994;59(Suppl):710S–718S.
116. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattini G, Patrono C: *In vivo* formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 1997;17:3230–3235.
117. Saggini A, Anogeianaki A, Angelucci D, Cianchetti E, D'Alessandro M, Maccauro G, Salini V, Caraffa A, Teté S, Conti F, Tripodi D, Fulcheri M, Frydas S, Shaik-Dasthagirisahab YB: Cholesterol and vitamins: revisited study. *J Biol Regul Homeost Agents* 2011;25:505–515.
118. Trapani L, Segatto M, Incerpi S, Pallottini V: 3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia? *Curr Mol Med* 2011;11:790–797.
119. Yung LM, Leung FP, Wong WT, Tian XY, Yung LH, Chen ZY, Yao XQ, Huang Y: Tea polyphenols benefit vascular function. *Inflammopharmacology* 2008;16:230–234.
120. Ginter E: Chronic vitamin C deficiency increases the risk of cardiovascular diseases. *Bratisl Lek Listy* 2007;108:417–421.
121. Quiñones M, Miguel M, Aleixandre A: The polyphenols, naturally occurring compounds with beneficial effects on cardiovascular disease. *Nutr Hosp* 2012;27:76–89.
122. Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC: Hypercholesterolemia and microvascular dysfunction: interventional strategies. *J Inflamm (Lond)* 2010;7:54.
123. Palombo C, Lubrano V, Sampietro T: Oxidative stress, F2-isoprostanes and endothelial dysfunction in hypercholesterolemia. *Cardiovasc Res* 1999;44:474–476.
124. Erejuwa O, Sulaiman SA, Wahab MSA, Sirajudeen KNS, Salleh MSM, Gurtu S: Differential responses to blood pressure and oxidative stress in streptozotocin-induced diabetic Wistar-Kyoto rats and spontaneously hypertensive rats: effects of antioxidant (honey) treatment. *Int J Mol Sci* 2011;12:1888–1907.
125. Erejuwa O, Sulaiman S, Ab Wahab M, Sirajudeen K, Salleh S, Gurtu S: Honey supplementation in spontaneously hypertensive rats elicits antihypertensive effect via amelioration of renal oxidative stress. *Oxid Med Cell Longev* 2012;2012:374037.
126. Rodrigo R, González J, Paoletto F: The role of oxidative stress in the pathophysiology of hypertension. *Hypertens Res* 2011;34:431–440.
127. Ostrow K, Wu S, Aguilar A, Bonner R, Suarez E, De Luca F: Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents. *J Pediatr* 2010;158:628–633.
128. Hirooka Y: Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. *Hypertens Res* 2011;34:407–412.
129. Banday A, Lokhandwala M: Oxidative stress causes renal angiotensin II Type 1 receptor upregulation, Na<sup>+</sup>/H<sup>+</sup> exchanger 3 overstimulation, and hypertension. *Hypertension* 2011;57:452–459.
130. Carlström M, Brown R, Edlund J: Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals. *Am J Physiol Renal Physiol* 2008;294:F362–F370.
131. Zatz R, Baylis C: Chronic nitric oxide inhibition model six years on. *Hypertension* 1998;32:958–964.

132. Nanri A, Moore M, Kono S: Impact of C-reactive protein on disease risk and its relation to dietary factors. *Asian Pac J Cancer Prev* 2007;8:167.
133. Block G, Jensen C, Dietrich M, Norkus EP, Hudes M, Packer L: Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. *J Am Coll Nutr* 2004;23:141–147.
134. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma DS: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation* 2003;107:1783–1790.
135. Devaraj S, Jialal I: Alpha tocopherol supplementation decreases serum C-reactive protein and monocytes interleukin-6 levels in normal volunteers and type 2 diabetic patients. *Free Radic Biol Med* 2000;29:790–792.
136. Patrick L, Uzick M: Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. *Altern Med Rev* 2001;6:248–271.
137. Chun OK, Chung SJ, Claycombe KJ, Song WO: Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. *J Nutr* 2008;138:753–760.
138. Qureshi MM, Singer MR, Moore LL: A cross-sectional study of food group intake and C-reactive protein among children. *Nutr Metab (Lond)* 2009;6:40.
139. Naseem KM: The role of nitric oxide in cardiovascular diseases. *Mol Aspects Med* 2005;26:33–65.
140. Bodzenta-Lukaszyk A, Gabryelewicz A, Lukaszyk A, Bielawiec M, Konturek JW, Domschke W: Nitric oxide synthase inhibition and platelet function. *Thromb Res* 1994;75:667–672.
141. Chen Y, Mehta J: Variable effects of L-arginine analogs on L-arginine–nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. *J Pharmacol Exp Ther* 1996;276:253–257.
142. World Health Organization physical status: the use and interpretation of anthropometry. WHO, Geneva, 1995.
143. Kassim M, Yusoff KM, Ong G, Sekaran S, Yusof MY, Mansor M: Gelam honey inhibits lipopolysaccharide-induced endotoxemia in rats through the induction of heme oxygenase-1 and the inhibition of cytokines, nitric oxide, and high-mobility group protein B1. *Fitoterapia* 2012;83:1054–1059.
144. Kassim M, Achoui M, Mansor M, Yusoff KM: The inhibitory effects of Gelam honey and its extracts on nitric oxide and prostaglandin E(2) in inflammatory tissues. *Fitoterapia* 2010;81:1196–1201.
145. Ahmad I, Jimenez H, Yaacob NS, Yusuf N: Tualang honey protects keratinocytes from ultraviolet radiation-induced inflammation and DNA damage. *Photochem Photobiol* 2012;88:1198–1204.
146. Owoyele BV, Adenekan OT, Soladoye AO: Effects of honey on inflammation and nitric oxide production in Wistar rats. *Zhong Xi Yi Jie He Xue Bao* 2011;9:447–452.
147. Foyet HS, Nana P, Chounfack E, Asongalem EA, Dimo T, Kamtchoung P: Protective effect of *Acanthus montanus* in carrageenan-induced models of local inflammation: inhibitory effect on nitric oxide (NO) production. *Pharmacologyonline* 2008;2:161–169.
148. Busserolles J, Gueux E, Rock E, Mazur A, Rayssiguier Y: Substituting honey for refined carbohydrates protects rats from hypertriglyceridemic and prooxidative effects of fructose. *J Nutr* 2002;132:3379–3382.
149. Soler C, Gil MI, Garcia-Viguera C, Thomas-Barberan FA: Flavonoid patterns of French honeys with different floral origin. *Apidologie* 1995;26:53–60.
150. van Acker SA, Tromp MN, Haenen GR, van der Vijgh WJ, Bast A: Flavonoids as scavengers of nitric oxide radical. *Biochem Biophys Res Commun* 1995;214:755–759.
151. Achike FI, Kwan CY: Nitric oxide, human diseases and the herbal products that affect the nitric oxide signalling pathway. *Clin Exp Pharmacol Physiol* 2003;30:605–615.
152. de Nigris F, Balestrieri ML, Williams-Ignarro S, D'Armiento FP, Fiorito C, Ignarro LJ, Napoli C: The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. *Nitric Oxide* 2007;17:50–54.
153. Fischer S: Is cyclooxygenase-2 important in skin carcinogenesis? *J Environ Pathol Toxicol Oncol* 2002;21:183–191.
154. Al-Waili NS, Saloom KY, Al-Waili T, Al-Waili A, Al-Waili H: Modulation of prostaglandin activity, part 1: prostaglandin inhibition in the management of nonrheumatologic diseases: immunologic and hematologic aspects. *Adv Ther* 2007;24:189–222.
155. Brandes RP, Fleming I, Busse R: Endothelial aging. *Cardiovasc Res* 2005;66:286–294.
156. Ferrari AU, Radaelli A, Centola M: Aging and the cardiovascular system. *J Appl Physiol* 2003;95:2591–2597.
157. Bunting S, Gryglewski S, Moncada S, Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. *Prostaglandins* 1976;12:897–913.
158. Gluais P, Vanhoutte PM, Félétou M: Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta. *Eur J Pharmacol* 2007;556:107–114.
159. Hirao A, Kondo K, Inui N, Umemura K, Ohashi K, Watanabe H: Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries. *Cardiovasc Res* 2008;79:161–168.
160. Gluais P, Lonchamp M, Morrow JD, Vanhoutte PM, Feletou M: Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. *Br J Pharmacol* 2005;146:834–845.
161. Nakano J, McCloy RB, Prancan AV: Circulatory and pulmonary airway responses to different mixtures of prostaglandins E2 and F2 $\alpha$  in dogs. *Eur J Pharmacol* 1973;24:61–66.
162. Hata A, Breyer R: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. *Pharmacol Ther* 2004;103:147–166.
163. Wong S, Leung C: Cyclooxygenase-2- derived prostaglandin F2 $\alpha$  mediates endothelium-dependent contractions in the aorta of hamsters with increased impact during aging. *Circ Res* 2009;104:228–235.
164. Lai J, Jin H, Yang R: Prostaglandin F2 $\alpha$  induces cardiac myocyte hypertrophy *in vitro* and cardiac growth *in vivo*. *Am J Physiol* 1996;271:H2197–H2208.
165. Szuldrzynski K, Zalewski J, Machnik A, Zmudka K: Elevated levels of 8-iso-prostaglandin F2 $\alpha$  in acute coronary syndromes are associated with systemic and local platelet activation. *Pol Arch Med Wewn* 2010;120:19–24.

166. LeLeiko RM, Vaccari CS, Sola S, Merchant N, Nagamia SH, Thoenes M, Khan BV: Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2009;104:638–643.
167. Matz RL, Andriantsitohaina R: Age-related endothelial dysfunction: potential implications for p49. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. *Pharmacol Ther* 2008;118:18–35.
168. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA: Platelet activation in unstable coronary disease. *N Engl J Med* 1986;315:983–989.
169. Fitzgerald DJ, Rocki W, Murray R, Mayo G, FitzGerald GA: Thromboxane A2 synthesis in pregnancy-induced hypertension. *Lancet* 1990;335:751–754.
170. Al-Waili NS: Effects of honey on the urinary total nitrite and prostaglandins concentration. *Int Urol Nephrol* 2005;37:107–111.
171. Bigler EJ, Whitton J: Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. *Cancer Epidemiol Biomarkers Prev* 2006;15:502–508.
172. Wen CT, Hussein SZ, Abdullah S, Karim NA, Makpol S, Mohd Yusof YA: Gelam and nenas honeys inhibit proliferation of HT 29 colon cancer cells by inducing DNA damage and apoptosis while suppressing inflammation. *Asian Pac J Cancer Prev* 2012;13:1605–1610.
173. Nemzer B, Rodriguez L, Hammond L, DiSilvestro R, Hunter J, Pietrkowski Z: Acute reduction of serum 8-iso-PGF2-alpha and advanced oxidation protein products *in vivo* by a polyphenol-rich beverage; a pilot clinical study with phytochemical and *in vitro* antioxidant characterization. *Nutr J* 2011;10:67.
174. Handy D, Loscalzo J: Homocysteine and atherothrombosis: diagnosis and treatment. *Curr Atheroscler Rep* 2003;5:276–283.
175. Oikawa S, Murakami K, Kawanishi S: Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis. *Oncogene* 2003;22:3530–3538.
176. Looker H, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Venkat Narayan KM, Knowler WC, Hanson RL: Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. *Diabetologia* 2003;46:766–772.
177. Alul K, Longo J, Marcotte AL, Campione AL, Moore MK, Lynch SM: Vitamin C protects low-density lipoprotein from homocysteine-mediated oxidation. *Free Radic Biol Med* 2003;34:881–891.
178. Cassone K, Laurenti O, Desideri G, Bravi MC, De Luca O, Marinucci MC, De Mattia G, Ferri C: L-Arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients. *Diabetologia* 2002;45:1120–1127.
179. WHO: Obesity: Preventing and managing the global epidemic. [WHO Technical report series No. 894]. World Health Organization, Geneva, 2000.
180. Poirier P, Eckel RH: The heart and obesity. In: *Hurst's The Heart* (Fuster V, Alexander RW, King S, O'Rourke RA, Roberts R, Wellens HJJ, eds.). McGraw-Hill Companies, New York, 2000, pp. 2289–2303.
181. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A: Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. *Int J Obes Relat Metab Disord* 1999;23:936–942.
182. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH: Weight and blood pressure: findings in hypertension screening of 1 million Americans. *JAMA* 1978;240:1607–1610.
183. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH: American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation* 2004;110:2952–2967.
184. Chepulis L: The effect of honey compared to sucrose, mixed sugars, and a sugar-free diet on weight gain in young rats. *J Food Sci* 2007;72:S224–S229.
185. Larson-Meyer DE, Willis KS, Willis LM, Austin KJ, Hart AM, Breton AB, Alexander BM: Effect of honey versus sucrose on appetite, appetite-regulating hormones, and postmeal thermogenesis. *J Am Coll Nutr* 2010;29:482–493.
186. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon K: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. *Circ Res* 2000;86:E85–E90.
187. Miller F, Gutterman D, Rios C, Heistad D, Davidson B: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. *Circ Res* 1999;82:1298–1305.
188. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, Diez J: Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. *Hypertension* 2000;35:1055–1061.
189. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 2001;88:E14–E22.
190. Sorata Y, Takahama U, Kimura M: Protective effect of quercetin and rutin on photosensitized lysis of human erythrocytes in the presence of hematoporphyrin. *Biochem Biophys Acta* 1982;799:313–317.
191. Karajibani M, Hashemi M, Montazerifar F, Bolouri A, Dikshit M: The status of glutathione peroxidase, superoxide dismutase, vitamins A, C, E and malondialdehyde in patients with cardiovascular disease in Zahedan, Southeast Iran. *J Nutr Sci Vitaminol (Tokyo)* 2009;55:309–316.
192. Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, Shachter NS, Fernandez ML: Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. *J Nutr* 2005;135:1911–1917.
193. Jeong YJ, Choi YJ, Kwon HM, Kang SW, Park HS, Lee M, Kang YH: Differential inhibition of oxidized LDL-induced apoptosis in human endothelial cells treated with different flavonoids. *Br J Nutr* 2005;93:581–591.
194. Fuhrman B, Volkova N, Coleman R, Aviram M: Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. *J Nutr* 2005;135:722–728.
195. Hubbard GP, Wolfram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA: Ingestion of onion soup high in quercetin in-

- hibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: A pilot study. *Br J Nutr* 2006;96:482–488.
196. Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, Stangl K, Baumann G, Stangl V: The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. *Biochem Biophys Res Commun* 2004;316:659–665.
197. Hallund J, Bugel S, Tholstrup T, Ferrari M, Talbot D, Hall WL, Reimann M, Williams CM, Wiinberg N: Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. *Br J Nutr* 2006;95:1120–1126.
198. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E: Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. *JAMA* 2007;298:49–60.
199. Park YK, Kim JS, Kang MH: Concord grape juice supplementation reduces blood pressure in Korean hypertensive men: Double-blind, placebo controlled intervention trial. *Biofactors* 2004;22:145–147.
200. Heiss C, Finis D, Kleinbongard P, Hoffmann A, Rassaf T, Kelm M, Sies H: Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. *J Cardiovasc Pharmacol* 2007;49:74–80.
201. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Urbe C, Schmitz HH, Kelm M: Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci USA* 2006;103:1024–1029.
202. Pearson DA, Paglieroni TG, Rein D, Wun T, Schramm DD, Wang JF, Holt RR, Gosselin R, Schmitz HH, Keen CL: The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. *Thromb Res* 2002;106:191–197.
203. Mathur S, Devaraj S, Grundy SM, Jialal I: Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. *J Nutr* 2002;132:3663–3667.
204. Schramm DD, Karim M, Schrader HR, Holt RR, Kirkpatrick NJ, Polagruto JA, Ensunsa JL, Schmitz HH, Keen CL: Food effects on the absorption and pharmacokinetics of cocoa flavanols. *Life Sci* 2003;73:857–869.
205. Middleton E, Kandaswami C, Theoharides T: The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. *Pharmacol Rev* 2000;52:673–751.
206. Jendekova L, Kojsova S, Andriantsitohaina R, Pechanova O: The time-dependent effects of Provinols on brain NO synthase activity in L-NAME-induced hypertension. *Physiol Res* 2006;55:S31–S37.
207. De Whalley CV, Rankin SM, Hoult J: Flavonoids inhibit the oxidative modification of low-density lipoproteins by macrophages. *Biochem Pharmacol* 1990;39:1743–1750.
208. Robak J, Gryglewski R: Flavonoids are scavengers of superoxide anion. *Biochem Pharmacol* 1988;37:83–88.
209. Appeldoorn MM, Venema DP, Peters TH, Koenen ME, Arts IC, Vincken JP, Gruppen H, Keijer J, Hollman PC: Some phenolic compounds increase the nitric oxide level in endothelial cells in vitro. *J Agric Food Chem* 2009;57:7693–7699.
210. Schmitt CA, Dirsch VM: Modulation of endothelial nitric oxide by plant-derived products. *Nitric Oxide* 2009;21:77–91.
211. Di Tomo P, Canali R, Ciavardelli D, Di Silvestre S, De Marco A, Giardinelli A, Pipino C, Di Pietro N, Virgili F, Pandolfi A:  $\beta$ -Carotene and lycopene affect endothelial response to TNF- $\alpha$  reducing nitro-oxidative stress and interaction with monocytes. *Mol Nutr Food Res* 2012;56:217–227.
212. Sánchez M, Galisteo M, Vera R, Villar IC, Zarzuelo A, Tarmargo J, Pérez-Vizcaíno F, Duarte J: Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. *J Hypertens* 2006;24:75–84.
213. D'Arcy B: Antioxidants in Australian floral honeys—Identification of health enhancing nutrient components. RIRDC Publication No. 05/040, 2005.
214. Inoue K, Murayama S, Seshimo F: Identification of phenolic compound in manuka honey as specific superoxide anion radical scavenger using electron spin resonance (ESR) and liquid chromatography with coulometric array detection. *J Sci Food Agric* 2005;85:872–878.
215. Fahey JW, Stephenson K: Pinostrobin from honey and Thai ginger (*Boesenbergia pandurata*): a potent flavonoid inducer of mammalian phase 2 chemoprotective and antioxidant enzymes. *J Agric Food Chem* 2002;50:7472–7476.
216. Perez RA, Iglesias MT, Pueyo E, Gonzalez M, de Lorenzo C: Amino acid composition and antioxidant capacity of Spanish honeys. *J Agric Food Chem* 2007;55:360–365.
217. Jaganathan SK, Mandal M: Antiproliferative effects of honey and of its polyphenols: a review. hindawi publishing corporation. *J Biomed Biotechnol* 2009;Article ID 830616, 13 pages.
218. Rakha MK, Nabil ZI, Hussein AA: Cardioactive and vasoactive effects of natural wild honey against cardiac malperformance induced by hyperadrenergic activity. *J Med Food* 2008;11:91–98.